- Home
- TNGX vs ALTI Comparison
TNGX vs ALTI Comparison
Compare TNGX & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ALTI
- Stock Information
- Founded
- TNGX 2014
- ALTI 2020
- Country
- TNGX United States
- ALTI United States
- Employees
- TNGX N/A
- ALTI N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ALTI Investment Managers
- Sector
- TNGX Health Care
- ALTI Finance
- Exchange
- TNGX Nasdaq
- ALTI Nasdaq
- Market Cap
- TNGX 723.2M
- ALTI 438.7M
- IPO Year
- TNGX N/A
- ALTI N/A
- Fundamental
- Price
- TNGX $7.62
- ALTI $3.68
- Analyst Decision
- TNGX Strong Buy
- ALTI
- Analyst Count
- TNGX 6
- ALTI 0
- Target Price
- TNGX $10.00
- ALTI N/A
- AVG Volume (30 Days)
- TNGX 1.5M
- ALTI 113.8K
- Earning Date
- TNGX 11-05-2025
- ALTI 11-07-2025
- Dividend Yield
- TNGX N/A
- ALTI N/A
- EPS Growth
- TNGX N/A
- ALTI N/A
- EPS
- TNGX N/A
- ALTI N/A
- Revenue
- TNGX $24,296,000.00
- ALTI $217,760,000.00
- Revenue This Year
- TNGX $20.42
- ALTI $19.78
- Revenue Next Year
- TNGX N/A
- ALTI $7.00
- P/E Ratio
- TNGX N/A
- ALTI N/A
- Revenue Growth
- TNGX N/A
- ALTI N/A
- 52 Week Low
- TNGX $1.03
- ALTI $2.33
- 52 Week High
- TNGX $9.84
- ALTI $5.00
- Technical
- Relative Strength Index (RSI)
- TNGX 63.92
- ALTI 29.52
- Support Level
- TNGX $6.38
- ALTI $3.66
- Resistance Level
- TNGX $6.90
- ALTI $4.32
- Average True Range (ATR)
- TNGX 0.45
- ALTI 0.17
- MACD
- TNGX 0.05
- ALTI -0.06
- Stochastic Oscillator
- TNGX 80.12
- ALTI 4.44
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ALTI AlTi Global Inc.
AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a proven track record with risk adjusted return characteristics.